Younger haploidentical donor versus older matched unrelated donor for patients with AML / MDS
American Journal of Hematology · 2023
DOI: 10.1002/ajh.26870 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Curtis Marcoux und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation, Myelodysplastic Syndromes, Graft vs Host Disease. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Optimal donor selection is fundamental to successful allogeneic hematopoietic cell transplantation (HCT), and donor age influences survival after both matched unrelated donor (MUD) and haploidentical donor HCT. Though recent studies have shown similar outcomes between MUD and haploidentical HCT, it is unknown if outcomes differ following HCT with younger haploidentical donors compared to HCT with older MUDs. Therefore, we performed a retrospective analysis comparing outcomes of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) patients who underwent HCT with younger (≤35 years) haploidentical donors ( n = 494) or older (>35 years) MUDs ( n = 1005). Patients in the haploidentical and MUD groups received post‐transplant cyclophosphamide (PTCy) and conventional graft‐versus‐host‐disease (GVHD) prophylaxis, respectively. In multivariate analysis, use of younger haploidentical donors was associated with improved overall survival (hazard ratio [HR] 0.81, 95% confidence interval [CI] 0.69–0.95, p = .01) and lower rates of grade II‐IV acute GVHD (HR 0.64, 95% CI 0.53–0.77, p < .001), grade III‐IV acute GVHD (HR 0.37, 95% CI 0.25–0.53, p < .001), and chronic GVHD (HR 0.49, 95% CI 0.40–0.60, p < .001). Relapse rates were similar among those who received myeloablative conditioning but were higher in patients of the younger haploidentical group who received reduced intensity conditioning (HR 1.49, 95%CI 1.18–1.88, p = .001). The younger haploidentical group had significantly lower non‐relapse mortality ≥3 months post‐HCT (HR 0.59, 95% CI 0.38–0.90, p = .02). Our data support the use of younger haploidentical donors with PTCy over older MUDs with conventional prophylaxis in patients with MDS or AML. Further studies on the importance of donor age in haploidentical and MUD HCT with PTCy prophylaxis are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
ORCID-Profile: Curtis Marcoux
Förderung
- NCI NIH HHS
Zitieren
APA
Marcoux, C., Marin, D., Ramdial, J., AlAtrash, G., Alousi, A. M., Oran, B., Kebriaei, P., Popat, U. R., Rezvani, K., Champlin, R. E., Shpall, E. J., & Mehta, R. S. (2023). Younger haploidentical donor versus older matched unrelated donor for patients with AML / MDS. American Journal of Hematology. https://doi.org/10.1002/ajh.26870
Vancouver
Marcoux C, Marin D, Ramdial J, AlAtrash G, Alousi AM, Oran B, et al. Younger haploidentical donor versus older matched unrelated donor for patients with AML / MDS. American Journal of Hematology. 2023. doi:10.1002/ajh.26870
BibTeX
@article{Marcoux2023,
author = {Marcoux, Curtis and Marin, David and Ramdial, Jeremy and AlAtrash, Gheath and Alousi, Amin M and Oran, Betul and Kebriaei, Partow and Popat, Uday R and Rezvani, Katayoun and Champlin, Richard E and Shpall, Elizabeth J and Mehta, Rohtesh S},
title = {Younger haploidentical donor versus older matched unrelated donor for patients with AML / MDS},
journal = {American Journal of Hematology},
year = {2023},
doi = {10.1002/ajh.26870}
}
EUVIMED